Interview: Frans Labuschagne – Head of Pharma, Bayer South Africa
The head of pharma for Bayer Southern Africa reveals how South Africa plays a key role in Bayer’s African strategy, with more than 60 percent of the continent’s total sales,…
Bristol-Myers Squibb is a global pharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. Our medicines are helping millions of patients around the world in their fight against cancer, cardiovascular disease, hepatitis B, HIV/AIDS and rheumatoid arthiritis.
Over the past decade, we have delivered 14 new products to patients with serious diseases. Four of these products are biologic products. Additional biologic compounds – as well as scores of other investigational medicines – are advancing through the development pipeline. Bristol-Myers Squibb is recognized as having one of the most productive R&D pipelines in the industry.
To accelerate the discovery and development of important new therapies, we are complementing and enhancing our internal capabilities with our String of Pearls strategy of innovative alliances, partnerships and acquisitions.
As a BioPharma leader, we believe what sets us apart is our commitment to helping patients prevail over serious diseases and our focus on finding innovative medicines to combat those diseases. Generating new ideas and thinking differently are at the heart of everything we do – making a difference in the lives of patients.
Contact
Woodmead North Office Park,
54 Maxwell Drive,
Woodmead, 2191,
Sandton,
Gauteng,
South Africa
The head of pharma for Bayer Southern Africa reveals how South Africa plays a key role in Bayer’s African strategy, with more than 60 percent of the continent’s total sales,…
The CEO of Pharma Dynamics explains why the company was the perfect match for Lupin, as the fastest growing, and largest independently owned acquirable pharmaceutical business in South Africa, why…
The chairman of PHARMISA reveals how pharmaceuticals has been designated as one of eight priority sectors of South African Government’s Industrial Policy Action Plan (IPAP), how South African life expectancy…
The CEO of Pierre Fabre for South Africa reveals how his focus has been on marketing the company brand locally, why the goal of the company is to develop business…
The EO of SAMED discusses recent regulations surrounding the medical device industry in South Africa, why South Africa remains the hub and the major gateway to Africa for medical devices…
The managing director of UTi Pharma reveals how UTi is no longer just an international forwarding company but covers a broad spectrum of activities; why as global business increases it…
The MD of Triclinium Clinical Development discusses how South Africa’s established First and Third World research opportunities and long-established GCP culture have made it a uniquely attractive country for clinical…
The country manager for BMS South Africa talks about the company’s first to market strategy, and how BMS has shifted the treatment paradigm for oncology in South Africa. Through our platform, we introduce the…
Iain Barton reveals how the acquisition of RTT Medical by IHS in 2013 has allowed Imperial to become the biggest pharma supply chain and general logistics services player on the African…
Peter Fuller provides us with an update on the integration of Covidien businesses, and explains how Medtronic is bringing innovation to South African patients and contributing to the improvement of the…
Adv. Leslie Sedibe, CEO of Proudly South African explains how the Proudly South African campaign aims to promote local products and services to ultimately address unemployment, and what his main…
The country president of Novartis South Africa reveals how Novartis has recently moved to new premises, demonstrating a clear commitment to continue investing in the country; why South Africa…
See our Cookie Privacy Policy Here